BioInvent extends collaboration with GlaxoSmithKline Biologicals

BioInvent extends collaboration with GlaxoSmithKline Biologicals Lund, Sweden: BioInvent International AB (SAX:BINV), specialist in the discovery and manufacture of human antibodies, today announced the extension of its collaboration with GlaxoSmithKline Biologicals, a world leader in the vaccine arena. Under the terms of the contract, BioInvent will supply antibodies to GlaxoSmithKline for use in research and development work for new vaccines. These human antibodies are developed using BioInvent's unique antibody library, n-CoDeRTM. The agreement - for a three year period - represents a substantial expansion in the level of co-operation between the two companies. The vaccine reagents are being developed using BioInvent's unique antibody library, n-CoDeR(TM). n-CoDeR(TM) is a collection of more than 10 billion distinct human antibody genes, from which it is possible to efficiently select antibodies with optimal properties. "The fact that GlaxoSmithKline Biologicals, which is part of one of the world's leading pharmaceutical companies focusing on vaccines, has chosen to expand its cooperation with us is an important milestone in our development and in the penetration of international markets. It is a proof that our technology and expertise is of a high standard and can deliver solutions of great importance for the development of the drugs of tomorrow," says Svein Mathisen, CEO of BioInvent International. For more information, please contact: BioInvent International AB Buchanan Communications Svein Mathisen Nicola How / Louise Bolton President and CEO Tel: +44 20 7466 5000 Tel: +46 46 286 85 67 Mobile: +46 708 97 82 13 E-mail: sm@bioinvent.com Notes to Editors: BioInvent International AB, listed on the O-list of the Swedish Exchange, is a biotechnology company devoted to providing state-of-the- art antibody technology to the pharmaceutical and biotech industry. A cornerstone is its proprietary human antibody gene library, n-CoDeR(TM). This is a collection of more than ten billion functional antibody genes that are ready to be screened against desired antigens. n-CoDeR(TM) has been used successfully for the isolation of antibody fragments with specificity for a number of antigens, including peptides, proteins and carbohydrates. BioInvent offers biotechnology and pharmaceutical companies access to n-CoDeR(TM) through collaborative research and development programs. BioInvent's capabilities in large-scale contract manufacturing of protein-based drugs through a state-of-the-art cGMP-certified facility further underpin its competitiveness in the antibody arena. BioInvent has been supplying monoclonal antibodies, fusion proteins and other recombinant proteins to the world's leading pharmaceutical and biotechnology companies for therapeutic use since 1988. These antibodies and proteins are used in all phases of clinical trials in both the US and across Europe. The cGMP-certified manufacturing facility is designed to meet FDA and EU regulations from early clinical development to commercial scale-up, with multi-kilogram annual capacity. BioInvent is headquartered in Lund, Sweden, employing a total of 115 people. For additional information, see www.bioinvent.com ------------------------------------------------------------ This information was brought to you by Waymaker http://www.waymaker.net The following files are available for download: http://www.waymaker.net/bitonline/2003/09/25/20030925BIT00940/wkr0001.doc http://www.waymaker.net/bitonline/2003/09/25/20030925BIT00940/wkr0002.pdf